Codolet, le 16/11/2018
Réf. LD-2018-R51-GB

To the attention of Laboratory Managers, Directors of Health Institutions and Local Vigilance Correspondents

URGENT : FIELD SAFETY NOTICE

Analyte	Product Reference
Chromogranin A	CGA-ELISA (Overnight protocol)
Chromogranin A	CGA-RIACT
PSA	PSA-RIACT
Free PSA	FPSA-RIACT
T3	OCPG07-T4 & OCPG57-T4
T4	OCPE07-T3 & OCPE57-T3
Aldosterone	ALDO-RIACT

Table 1 – Identification of the products

Dear Sir, Dear Madam, Dear Customers

This document contains an important information regarding biotin interference in some Cisbio Bioassays immunoassays and therefore, requires special attention.

OBJECT: Within the context of increasing biotin intakes through food supplements and medical treatments, several cases of biotin interference with immunoassays have been reported to the French Health Authority (ANSM). This interference was observed in immunoassays for which biotin is part of the functional principle of the assay and when samples with high biotin concentrations were reported.

Cisbio Bioassays identified which of its immunoassays were at risk of being affected by an interference with biotin and has conducted the relevant testing in order to determine whether biotin concentrations above the normal values may interfere with these particular products. To do so, several samples were spiked with D-Biotin at variable concentrations ranging from 1.5ng/mL to 1200 ng/mL and were then assayed with the relevant Cisbio Bioassays products.

RESULTS: The results of the testing carried out emphasized that biotin may interfere with the following products: CGA ELISA (overnight protocol), CGA-RIACT, PSA-RIACT, FPSA-RIACT, OCPG07-T4, OCPG57-T4, OCPE07-T3, OCPE57-T3 and ALDO-RIACT. A summary of the concentrations above which biotin interference was measured is provided in Table 2 below.

REFERENCE	LIMIT OF BIOTIN INTERFERENCE
PSA-RIACT	> 300 ng/mL
CGA-ELISA (Overnight protocol)	> 15 ng/mL
CGA-RIACT	> 15 ng/mL
OCPG07-T4 & OCPG57-T4	> 15 ng/mL
OCPE07-T3 & OCPE57-T3	> 15 ng/mL
ALDO-RIACT	> 1.5 ng/mL
FPSA-RIACT	> 1.5 ng/mL

Table 2 – Summary of biotin interference testing results

Other Cisbio Bioassays products using biotin in their functioning principle were also tested and did not show any biotin interference.

Cisbio Bioassays | Parc Marcel Boiteux | BP 84175 | 30200 Codolet | France | +33 (0)466 796 700 | www.cisbio.com SAS
au capital de 13 793 759 Euros | RCS Nîmes 519 954 986

RISKS: In the event of biotin interferences, falsely elevated results may be observed in immunoassays based on the competition principle (ALDO-RIACT, OCPG07-T4, OCPG57-T4, OCPE07-T3 and OCPE57-T3) and falsely lowered results may be observed in sandwich immunoassays (PSA-RIACT, FPSA-RIACT, CGA ELISA and CGA-RIACT). These results could lead to erroneous conclusions regarding the health condition of the patient.
It is, therefore, recommended to carefully consider the clinical features of the patient when interpreting the results rendered by the above-mentioned immunoassays.

Based on this new information, Cisbio Bioassays leaves to the laboratories' discretion the necessity of reassessing the results obtained with patients' samples presenting with high biotin concentrations.

CORRECTIVE ACTION: Cisbio Bioassays has already initiated an instruction for use updating process for the IFUs related to the products listed in Table 2 above in order to emphasize the risk of interference in samples of patients under biotin treatment. The update of the IFUs is expected to the completed by the 31st of January, 2019.

The periods of placing on the market of products associated with updated instructions for use are identified in Table 3 below.

Reference	Date of placing on the market	Version of the instructions for use leaflet
PSA-RIACT	January 2019	024
FPSA-RIACT	January 2019	022
CGA-ELISA (Overnight protocol)	June 2018	014
CGA-RIACT	December 2018	025
ALDO-RIACT	December 2018	020
OCPG07-T4	December 2018	021
OCPG57-T4	December 2018	004
OCPE07-T3	December 2018	019
OCPE57-T3	December 2018	004

Table 3 – Identification of the periods of placing on the market of products containing an updated instructions for use leaflet mentioning biotin interferences.

ACTIONS TO BE TAKEN BY USERS:

- ⇨ To share this information with your clinician and/or any other person who may needs it.
- ⇨ To assess the necessity to review the results already obtained for high biotin concentration samples.
- ⇨ To acknowledge receipt of this information letter to your local distributor

The French Health Authority, ANSM, was informed of this communication.

Your local distributor remains at your disposal for any further information you may need.

Sincerely,

[redacted]

Cisbio Bioassays | Parc Marcel Boiteux | BP 84175 | 30200 Codolet | France | +33 (0)466 796 700 | www.cisbio.com SAS
au capital de 13 793 759 Euros | RCS Nîmes 519 954 986